Structure-activity relationship and cardiac safety of 2-aryl-2-(pyridin-2-yl)acetamides as a new class of broad-spectrum anticonvulsants derived from Disopyramide

Autor: Bartłomiej Szulczyk, Jules C. Hancox, Jadwiga Turło, Eliska Mistrova, Marek Król, Jitka Sviglerova, Aziza El Harchi, Grzegorz M. Popowicz, Milan Stengl, Piotr Konopelski, Yihong Zhang, Dagmar Jarkovska, Martyna Z. Wróbel, Maciej Dawidowski, Andrzej Chodkowski, Marcin Ufnal, Piotr Szuberski, Piotr Podsadni
Jazyk: angličtina
Rok vydání: 2020
Předmět:
Male
medicine.medical_treatment
01 natural sciences
Biochemistry
Epilepsy
chemistry.chemical_compound
Mice
Sodium channel blocker
Drug Discovery
Acetamides
voltage-gated sodium channel
anticonvulsant agent
Electroshock
Molecular Structure
disopyramide
Anticonvulsant Agent
Anticonvulsants
Female
Disopyramide
Injections
Intraperitoneal

medicine.drug
Stereochemistry
Injections
Subcutaneous

sodium channel blocker
drug repositioning
drug discovery
Structure-Activity Relationship
In vivo
Seizures
medicinal chemistry
medicine
Structure–activity relationship
Animals
Rats
Wistar

Molecular Biology
Dose-Response Relationship
Drug

010405 organic chemistry
Aryl
Organic Chemistry
structure-activity relationships
refractory epilepsy
medicine.disease
0104 chemical sciences
Rats
010404 medicinal & biomolecular chemistry
Anticonvulsant
chemistry
Pentylenetetrazole
cardiac safety
Zdroj: Dawidowski, M, Król, M, Szulczyk, B, Chodkowski, A, Podsadni, P, Konopelski, P, Ufnal, M, Szuberski, P, Wróbel, M Z, Zhang, Y, El Harchi, A, Hancox, J C, Jarkovska, D, Mistrova, E, Sviglerova, J, Štengl, M, Popowicz, G M & Turło, J 2020, ' Structure-activity relationship and cardiac safety of 2-aryl-2-(pyridin-2-yl)acetamides as a new class of broad-spectrum anticonvulsants derived from Disopyramide ', Bioorganic chemistry, vol. 98, 103717 . https://doi.org/10.1016/j.bioorg.2020.103717
DOI: 10.1016/j.bioorg.2020.103717
Popis: A series of 2-aryl-2-(pyridin-2-yl)acetamides were synthesized and screened for their anticonvulsant activity in animal models of epilepsy. The compounds were broadly active in the ‘classical’ maximal electroshock seizure (MES) and subcutaneous Metrazol (scMET) tests as well as in the 6 Hz and kindling models of pharmacoresistant seizures. Furthermore, the compounds showed good therapeutic indices between anticonvulsant activity and motor impairment. Structure-activity relationship (SAR) trends clearly showed the highest activity resides in unsubstituted phenyl derivatives or compounds having ortho- and meta- substituents on the phenyl ring. The 2-aryl-2-(pyridin-2-yl)acetamides were derived by redesign of the cardiotoxic sodium channel blocker Disopyramide (DISO). Our results show that the compounds preserve the capability of the parent compound to inhibit voltage gated sodium currents in patch-clamp experiments; however, in contrast to DISO, a representative compound from the series 1 displays high levels of cardiac safety in a panel of in vitro and in vivo experiments.
Databáze: OpenAIRE